Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Every dose, schedule, and supply quantity on this page is reported for educational research context and mirrors the published REDEFINE Phase 3 trial protocol
contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 Risk of diabetic retinopathy complications in patients with pre-existing retinopathy Potential for acute kidney injury, particularly related to dehydration Caution or avoidance in severe gastroparesis or severe gastrointestinal disease Suicidality warning for weight-management indications (Wegovy, Saxenda) Potential for altered absorption of oral medications due to delayed gastric emptying In older adults with cognitive impairment, medication adherence may be challenging, and gastrointestinal side effects could lead to dehydration or nutritional deficiencies
Wash your face/body with your favorite cleanser 2
The Developed Pharmacokinetic Models for GLP-1 RAs and a Dual GLP-1/GIP RA Pharmacokinetic models of GLP-1 RAs and a dual GLP-1/GIP RA have been developed as clinical support tools, enabling the prediction of their pharmacokinetic behavior across different clinical scenarios (Table 6)
It is currently under clinical investigation and has not yet received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA)
Further research is needed to fully understand the mechanisms and therapeutic potential of BPC-157 in mood and behavior regulation
